TOKYO -- Japanese drugmaker Daiichi Sankyo aims to start exporting its vaccines to international markets, starting with Southeast Asia by 2030.
Vaccine demand depends on which infectious diseases are circulating at the moment. By tapping demand overseas, the company aims to secure production volume and maintain its vaccine-manufacturing structure, including equipment and necessary personnel.
